Funding for this research was provided by:
Japan Agency for Meical Research and Development (JP21fk0210051)
Japan Society for Promotion of Science (JP20K09104)
Received: 12 April 2022
Accepted: 27 July 2022
First Online: 3 August 2022
: This phase I clinical trial was approved by the Special Committee for Regenerative Medicine, Hiroshima University, and registered with the Japan Registry of Clinical Trials (jRCTa060190036). This trial was designed and conducted following the Declaration of Helsinki. A written informed consent was obtained from all patients before enrollment in the study.
: Not applicable.
: The authors of this manuscript have no conflict of interest to disclose.